| abstract |
New monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that specifically bind to human IGF-1R and human ErbB3 are provided herein. Exemplary antibodies inhibit signaling through either or both of IGF-1R and ErbB3. An exemplary multivalent protein comprises at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments, the binding site can be bound via an immunoglobulin constant region. Novel anti-ErbB3 antibodies and anti-IGF-1R antibodies (eg, monoclonal antibodies) are also provided. |